TechNet-21 - Forum

  1. Moderator
  2. Supply chain and logistics
  3. Thursday, 12 September 2013
The need to keep vaccines in a 2°C to 8°C cold chain is a constraining factor for many immunization campaigns due to limited storage capacity and/or limited ice pack freezing capacity; supplementary immunization activities planned across sub-Saharan Africa to introduce MenAfriVac™ are a good example. In 2012, the licence for the Serum Institute of India’s meningitis A vaccine, MenAfriVac®, was changed based on a thorough review of scientific data by regulatory authorities and the World Health Organization (WHO) to allow for the use of the vaccine for a period of up to 4 days at temperatures of up to 40°C in a controlled temperature chain (CTC). WHO has published three documents to provide support on use and adoption of CTC: 1. This document gives guidance on how to use the CTC: Use of MenAfriVac (meningitis A vaccine) in a controlled temperature chain (CTC) during campaigns Use of MenAfriVac (meningitis A vaccine) in a controlled temperature chain (CTC) during campaigns 2. A training module that teaches how to integrate the CTC into your routine immunization programme: Training module for organizing immunization sessions 3. This document tells countries how to adapt the generic training module to the local situation: Adaptation guide and facilitator's guide


There are no replies made for this post yet.
Be one of the first to reply to this post!